🧠Cognitive Enhancement

An oligopeptide derived from angiotensin IV that is reported to be 10 million times more potent than BDNF at enhancing cognitive function through hepatocyte growth factor (HGF) signaling.

A naturally occurring anti-inflammatory tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH), studied for its potent anti-inflammatory effects in the gut, skin, and systemically.

A D-retro-inverso peptide that selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction, representing a targeted senolytic approach to aging.

The only human cathelicidin antimicrobial peptide, a 37-amino acid peptide beginning with two leucines, with broad-spectrum antimicrobial, anti-biofilm, immunomodulatory, and wound healing properties.

A porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids, used clinically in many countries for stroke recovery, traumatic brain injury, and dementia.

A mitochondria-targeted tetrapeptide that concentrates in the inner mitochondrial membrane, protecting cardiolipin and restoring bioenergetics in aging and disease.

A mitochondria-derived peptide that acts as an exercise mimetic, improving metabolic health, insulin sensitivity, and physical performance through AMPK activation.

A small synthetic peptide derived from ciliary neurotrophic factor (CNTF) that promotes neurogenesis and enhances cognitive function by inhibiting leukemia inhibitory factor (LIF) signaling.

A mitochondria-derived 24-amino acid peptide with potent cytoprotective and neuroprotective effects, being studied for Alzheimer's disease, metabolic health, and longevity.

A 28-amino acid thymic peptide that modulates immune function, approved in multiple countries for hepatitis B and used as an immune enhancer in cancer and infectious disease.

A synthetic tetrapeptide based on the natural epithalamin peptide from the pineal gland, studied for its ability to activate telomerase and potentially slow cellular aging.

A synthetic hexapeptide growth hormone secretagogue considered to offer the best balance of potency and side effect profile among the GHRP family.

A synthetic heptapeptide derived from ACTH(4-10) with a Pro-Gly-Pro C-terminal extension, used as a nootropic and neuroprotectant with regulatory approval in Russia for stroke and cognitive disorders.

A synthetic hexapeptide growth hormone secretagogue that potently stimulates GH release through the ghrelin receptor, with additional cardioprotective properties.

A synthetic heptapeptide anxiolytic derived from the endogenous immunomodulatory peptide tuftsin, with an added Pro-Gly-Pro C-terminus, approved in Russia for anxiety and neurasthenia.

A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.

An investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, producing unprecedented weight loss of up to 24% in clinical trials.

The arginine salt form of BPC-157, optimized for oral bioavailability and stability, used interchangeably with BPC-157 for tissue healing and gut repair.

An investigational dual glucagon and GLP-1 receptor agonist being developed for obesity and MASH (metabolic dysfunction-associated steatohepatitis) with significant liver fat reduction.

A naturally occurring nonapeptide that promotes delta-wave deep sleep, modulates stress hormones, and has potential applications in insomnia, pain, and withdrawal syndromes.

A 28-amino acid neuropeptide with broad immunomodulatory, vasodilatory, and anti-inflammatory effects, used in CIRS (Chronic Inflammatory Response Syndrome) protocols and researched for pulmonary conditions.

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and obesity management, with cardiovascular and neuroprotective benefits.

An FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes with proven cardiovascular benefits and convenient single-use pen delivery.

The first GLP-1 receptor agonist approved for type 2 diabetes, originally derived from Gila monster venom, available in twice-daily and once-weekly formulations.

A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's and Alzheimer's disease, repurposed as a potent weight-loss agent.